Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 254

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 254
---
 | 3,675 | -1 |     |              |       - |    |     | $     |  26,250 |    |
| Shami Patel         |     | $           |  7,500 |    |     |                | 2,550 | -2 |     |              | 105,000 | -2 |     | $     | 115,050 |    |
| Robyn Rapaport      |     | $           | 18,750 | -4 |     |                | 1,125 | -3 |     |              |       - |    |     | $     |  26,250 | -4 |

| (1) | This                                                                                                                                    
 includes (i) option to purchase 1,125 shares of Common Stock  granted to the non-employee directors on March 25, 2024 at an             
 exercise price of $177.00 per share and (ii) option to purchase 2,550 shares of Common Stock, which vest in two equal installments      
 subject to the satisfaction of certain performance criteria; on December 2, 2024, the board of directors confirmed that the performance 
 criteria had been met with regards to one installment, resulting in the vesting of 1,275 shares under (ii).                             |

| (2) | This                                                                                                                                
 includes the option to purchase 2,550 shares of Common Stock, which vest in two equal installments subject to the satisfaction of   
 certain performance criteria; on December 2, 2024, the board of directors confirmed that the performance criteria had been met with 
 regards to one installment, resulting in the vesting of 1,275 shares. Mr. Patel received $75,000 in consulting fees pursuant to the 
 agreement between Mr. Patel and the Company.                                                                                        |

| (3) | This                                                                                                                                
 includes the option to purchase 1,125 shares of Common Stock  granted to the non-employee director on March 25, 2024 at an exercise 
 price of $177.00 per share; such award was forfeited following the directors resignation from the board of directors.               |

| (4) | This includes the non-employee director compensation for the director which award was forfeited following the director’s resignation from the board of directors. |

159 PRINCIPAL STOCKHOLDERS The following table sets forth information regarding the beneficial ownership of our common stock as of January 8, 2025, by:

|